A systematic review on the efficacy and safety of low molecular weight heparin as an anticancer therapeutic in preclinical animal models.

[1]  M. Lalu,et al.  The Efficacy and Safety of Low Molecular Weight Heparin Administration to Improve Survival of Cancer Patients: A Systematic Review and Meta-Analysis , 2020, Thrombosis and Haemostasis.

[2]  H. Versteeg,et al.  A systematic review on the effects of direct oral anticoagulants on cancer growth and metastasis in animal models. , 2020, Thrombosis research.

[3]  Xian-jie Shi,et al.  Generation and application of patient-derived xenograft models in pancreatic cancer research , 2019, Chinese medical journal.

[4]  D. Ou,et al.  Mouse Models for Immunotherapy in Hepatocellular Carcinoma , 2019, Cancers.

[5]  R. Souza,et al.  Cancer-associated thrombosis: the when, how and why , 2019, European Respiratory Review.

[6]  L. Alberio,et al.  Direct Oral Anticoagulant Drugs: On the Treatment of Cancer-Related Venous Thromboembolism and their Potential Anti-Neoplastic Effect , 2019, Cancers.

[7]  Dongsheng Wang,et al.  Role of dalteparin sodium on the growth of cancer cells and tumor-associated angiogenesis in A549 human lung cancer cell line and grafted mouse model , 2018, Journal of cancer research and therapeutics.

[8]  Z. Mousavi,et al.  Effects of Enoxaparin Emulsion on Dimethylbenzanthracene-induced Breast Cancer in Female Rats , 2018 .

[9]  Wei Chen,et al.  Antitumor effects of nadroparin combined with radiotherapy in Lewis lung cancer models , 2018, OncoTargets and therapy.

[10]  M. Lanuti,et al.  Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy , 2018, Disease Models & Mechanisms.

[11]  D. Garcia,et al.  Managing thrombosis in cancer patients , 2018, Research and practice in thrombosis and haemostasis.

[12]  Dietmar W Hutmacher,et al.  Rational Design of Mouse Models for Cancer Research. , 2018, Trends in biotechnology.

[13]  Ana Mlinarić,et al.  Dealing with the positive publication bias: Why you should really publish your negative results , 2017, Biochemia medica.

[14]  Peng Li,et al.  Current status and perspectives of patient-derived xenograft models in cancer research , 2017, Journal of Hematology & Oncology.

[15]  T. Mueller,et al.  The Impact of the Low Molecular Weight Heparin Tinzaparin on the Sensitization of Cisplatin-Resistant Ovarian Cancers—Preclinical In Vivo Evaluation in Xenograft Tumor Models , 2017, Molecules.

[16]  J. Marshall,et al.  Evaluating mesenchymal stem cell therapy for sepsis with preclinical meta-analyses prior to initiating a first-in-human trial , 2016, eLife.

[17]  P. Morel,et al.  Enoxaparin Attenuates Mouse Colon Cancer Liver Metastases by Inhibiting Heparanase and Interferon-γ-inducible Chemokines. , 2016, Anticancer research.

[18]  J. McGowan,et al.  PRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement. , 2016, Journal of clinical epidemiology.

[19]  Prakrit V. Jena,et al.  P-selectin is a nanotherapeutic delivery target in the tumor microenvironment , 2016, Science Translational Medicine.

[20]  Matthew Wei,et al.  The Anti-Factor Xa Range For Low Molecular Weight Heparin Thromboprophylaxis , 2015, Hematology reports.

[21]  Chi-Ping Day,et al.  Preclinical Mouse Cancer Models: A Maze of Opportunities and Challenges , 2015, Cell.

[22]  J. Utikal,et al.  von Willebrand factor fibers promote cancer-associated platelet aggregation in malignant melanoma of mice and humans. , 2015, Blood.

[23]  P. Pattyn,et al.  Microvascular effects of the low molecular weight heparins in a colorectal xenograft model: an intravital microscopy study. , 2015, The Journal of surgical research.

[24]  S. Mousa,et al.  Anti-metastasis efficacy and safety of non-anticoagulant heparin derivative versus low molecular weight heparin in surgical pancreatic cancer models. , 2015, International journal of oncology.

[25]  Yan Pan,et al.  Enoxaparin Sensitizes Human Non–Small-Cell Lung Carcinomas to Gefitinib by Inhibiting DOCK1 Expression, Vimentin Phosphorylation, and Akt Activation , 2015, Molecular Pharmacology.

[26]  P. Shekelle,et al.  Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement , 2015, Systematic Reviews.

[27]  N. Shrivastava,et al.  An improved and versatile immunosuppression protocol for the development of tumor xenograft in mice. , 2014, Anticancer research.

[28]  Weiwei Yin,et al.  Combination therapy with low molecular weight heparin and Adriamycin results in decreased breast cancer cell metastasis in C3H mice , 2014, Experimental and therapeutic medicine.

[29]  Xiao Han,et al.  Tissue factor in tumor microenvironment: a systematic review , 2014, Journal of Hematology & Oncology.

[30]  S. Mousa,et al.  Suppression of pancreatic cancer by sulfated non-anticoagulant low molecular weight heparin. , 2014, Cancer letters.

[31]  A. Lazo-Langner,et al.  The effect of low molecular weight heparin on survival in cancer patients: an updated systematic review and meta‐analysis of randomized trials , 2014, Journal of thrombosis and haemostasis : JTH.

[32]  L. Borsig,et al.  The role of VLA-4 binding for experimental melanoma metastasis and its inhibition by heparin. , 2014, Thrombosis research.

[33]  M. Ghert,et al.  Lost in translation: animal models and clinical trials in cancer treatment. , 2014, American journal of translational research.

[34]  G. Hannon,et al.  Patient-derived tumor xenografts: transforming clinical samples into mouse models. , 2013, Cancer research.

[35]  H. Tsuchiya,et al.  Low molecular weight heparin suppresses receptor for advanced glycation end products‐mediated expression of malignant phenotype in human fibrosarcoma cells , 2013, Cancer science.

[36]  Mirosława Püsküllüoğlu,et al.  The antineoplastic effect of low-molecular-weight heparins – a literature review , 2013, Contemporary oncology.

[37]  James A. Anderson,et al.  Should preclinical studies be registered? , 2012, Nature Biotechnology.

[38]  H. Hamm,et al.  Thrombin induces osteosarcoma growth, a function inhibited by low molecular weight heparin in vitro and in vivo , 2012, Cancer.

[39]  O. Kallioniemi,et al.  Heparin-like Polysaccharides Reduce Osteolytic Bone Destruction and Tumor Growth in a Mouse Model of Breast Cancer Bone Metastasis , 2012, Molecular Cancer Research.

[40]  Xueying Sun,et al.  Modulating the interaction of CXCR4 and CXCL12 by low-molecular-weight heparin inhibits hepatic metastasis of colon cancer , 2012, Investigational New Drugs.

[41]  O. Kallioniemi,et al.  Abstract 845: Heparin-like polysaccharides reduce osteolytic bone destruction and tumor growth in a mouse model of breast cancer bone metastasis , 2011 .

[42]  H. Atkins,et al.  Abstract 5235: Surgical stress promotes the development of cancer metastases by coagulation dependent inhibition of natural-killer cell mediated tumor cell clearance , 2011 .

[43]  S. Mousa,et al.  Increased tumor uptake of chemotherapeutics and improved chemoresponse by novel non-anticoagulant low molecular weight heparin. , 2011, Anticancer research.

[44]  R. Kerbel,et al.  Mouse models of advanced spontaneous metastasis for experimental therapeutics , 2011, Nature Reviews Cancer.

[45]  S. Yale,et al.  Virchow’s Contribution to the Understanding of Thrombosis and Cellular Biology , 2010, Clinical Medicine & Research.

[46]  C. V. van Noorden,et al.  A Low Molecular Weight Heparin Inhibits Experimental Metastasis in Mice Independently of the Endothelial Glycocalyx , 2010, PloS one.

[47]  Susanne M. Smorenburg,et al.  Prophylactic plasma levels of the low molecular weight heparin nadroparin does not affect colon cancer tumor development in mouse liver. , 2010, Thrombosis research.

[48]  D. Howells,et al.  Publication Bias in Reports of Animal Stroke Studies Leads to Major Overstatement of Efficacy , 2010, PLoS biology.

[49]  P. Pattyn,et al.  The low-molecular-weight heparin, nadroparin, inhibits tumour angiogenesis in a rodent dorsal skinfold chamber model , 2010, British Journal of Cancer.

[50]  G. Merli,et al.  Pharmacological and clinical differences between low-molecular-weight heparins: implications for prescribing practice and therapeutic interchange. , 2010, P & T : a peer-reviewed journal for formulary management.

[51]  P. Reitsma,et al.  Long‐term thrombin inhibition promotes cancer cell extravasation in a mouse model of experimental metastasis , 2009, Journal of thrombosis and haemostasis : JTH.

[52]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement , 2009, BMJ.

[53]  S. Mousa,et al.  Anti-cancer properties of low-molecular-weight heparin: Preclinical evidence , 2009, Thrombosis and Haemostasis.

[54]  R. White,et al.  Epidemiology of cancer-related venous thromboembolism. , 2009, Best practice & research. Clinical haematology.

[55]  P. Reitsma,et al.  Differential effects of anticoagulants on tumor development of mouse cancer cell lines B16, K1735 and CT26 in lung , 2009, Clinical & Experimental Metastasis.

[56]  M. Roudier,et al.  Use of low-molecular-weight heparin to decrease mortality in mice after intracardiac injection of tumor cells. , 2009, Comparative medicine.

[57]  A. Falanga,et al.  Heparin in tumor progression and metastatic dissemination. , 2007, Seminars in thrombosis and hemostasis.

[58]  R. Sasisekharan,et al.  Low Molecular Weight Heparins: Structural Differentiation by Bidimensional Nuclear Magnetic Resonance Spectroscopy , 2007, Seminars in thrombosis and hemostasis.

[59]  Simi Ali,et al.  Inhibition of CXCR4-Mediated Breast Cancer Metastasis: A Potential Role for Heparinoids? , 2007, Clinical Cancer Research.

[60]  S. Mousa,et al.  Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin , 2006, Thrombosis and Haemostasis.

[61]  J. Chorostowska-Wynimko,et al.  Comparison of the effects of enoxaparin and nadroparin on tumor angiogenesis in mice , 2006 .

[62]  X. Weng,et al.  [The effect of VEGF antisense oligonucleotides combined with low molecular weight heparin on the growth and metastasis of mice Lewis lung cancer]. , 2006, Zhonghua yi xue za zhi.

[63]  R. Henschler,et al.  The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo , 2006, Thrombosis and Haemostasis.

[64]  Hidetada Sasaki,et al.  A comparison of the effects of unfractionated heparin, dalteparin and danaparoid on vascular endothelial growth factor‐induced tumour angiogenesis and heparanase activity , 2005, British journal of pharmacology.

[65]  A. Varki,et al.  Differential Metastasis Inhibition by Clinically Relevant Levels of Heparins—Correlation with Selectin Inhibition, Not Antithrombotic Activity , 2005, Clinical Cancer Research.

[66]  L. Binderup,et al.  Non-anti-coagulant heparin inhibits metastasis but not primary tumor growth. , 2005, Oncology reports.

[67]  B. Szende,et al.  Effect of Fraxiparine and heparin on experimental tumor metastasis in mice. , 2005, Anticancer research.

[68]  Susanne M. Smorenburg,et al.  The effect of low molecular weight heparin on survival in patients with advanced malignancy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  B. Klaunberg,et al.  In vivo bioluminescence imaging. , 2004, Comparative medicine.

[70]  Michael Thomas,et al.  Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  H. Lippert,et al.  Effect of low molecular weight heparin on intra-abdominal metastasis in a laparoscopic experimental study , 2004, International Journal of Colorectal Disease.

[72]  S. Mousa,et al.  Antimetastatic effect of tinzaparin, a low‐molecular‐weight heparin , 2003, Journal of thrombosis and haemostasis : JTH.

[73]  M. Prins,et al.  Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. , 2003, The New England journal of medicine.

[74]  M. Levine,et al.  Venous Thromboembolism and Cancer: Risks and Outcomes , 2003, Circulation.

[75]  R. White,et al.  Low‐Molecular‐Weight Heparins: Are they all the Same? , 2003, British journal of haematology.

[76]  A. Howlett,et al.  Improved effect of an antiangiogenic tyrosine kinase inhibitor (SU5416) by combinations with fractionated radiotherapy or low molecular weight heparin. , 2003, Neoplasia.

[77]  H. Breddin.  Reviparin sodium – a new low molecular weight heparin , 2002, Expert opinion on pharmacotherapy.

[78]  A. Varki,et al.  P-selectin, carcinoma metastasis and heparin: novel mechanistic connections with therapeutic implications. , 2001, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[79]  Susanne M. Smorenburg,et al.  In vivo treatment of rats with unfractionated heparin (UFH) or low molecular weight heparin (LMWH) does not affect experimentally induced colon carcinoma metastasis , 1999, Clinical & Experimental Metastasis.

[80]  Hua Dong.  Effect of low molecular weight heparin on growth,metastasis,and CXCR4 expression of orthotopicly transplanted gastric tumor in nude mice , 2010 .

[81]  Jun Yan,et al.  Inhibitory effect of dalteparin sodium on the growth of early-stage hepatocellular carcinoma , 2008 .

[82]  A. Varki,et al.  Heparin attenuates metastasis mainly due to inhibition of P- and L-selectin, but non-anticoagulant heparins can have additional effects. , 2007, Thrombosis research.

[83]  E. Raso,et al.  Selective antimetastatic effect of heparins in preclinical human melanoma models is based on inhibition of migration and microvascular arrest , 2005, Clinical & Experimental Metastasis.

[84]  F. Marcucci,et al.  Treatment with modified heparins inhibits experimental metastasis formation and leads, in some animals, to long-term survival. , 1996, Invasion & metastasis.